48 results on '"Medina-Echeverz J"'
Search Results
2. Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
- Author
-
Bella-Carreño, Á. (Ángela), Di-Trani, C.A. (Carla Augusta), Fernández-Sendín, M. (Myriam), Arrizabalaga, L. (Leire), Cirella, A. (Assunta), Teijeira, A. (Álvaro), Medina-Echeverz, J. (José), Melero, I. (Ignacio), Berraondo, P. (Pedro), and Aranda, F. (Fernando)
- Subjects
Animal model ,Peritoneal microenvironment ,Translational research ,Peritoneal carcinomatosis ,Metastasis - Abstract
Simple Summary Peritoneal carcinomatosis mouse models as a platform to test, improve and/or predict the appropriate therapeutic interventions in patients are crucial to providing medical advances. Here, we overview reported mouse models to explore peritoneal carcinomatosis in translational biomedical research. Peritoneal carcinomatosis of primary tumors originating in gastrointestinal (e.g., colorectal cancer, gastric cancer) or gynecologic (e.g., ovarian cancer) malignancies is a widespread type of tumor dissemination in the peritoneal cavity for which few therapeutic options are available. Therefore, reliable preclinical models are crucial for research and development of efficacious treatments for this condition. To date, a number of animal models have attempted to reproduce as accurately as possible the complexity of the tumor microenvironment of human peritoneal carcinomatosis. These include: Syngeneic tumor cell lines, human xenografts, patient-derived xenografts, genetically induced tumors, and 3D scaffold biomimetics. Each experimental model has its own strengths and limitations, all of which can influence the subsequent translational results concerning anticancer and immunomodulatory drugs under exploration. This review highlights the current status of peritoneal carcinomatosis mouse models for preclinical development of anticancer drugs or immunotherapeutic agents.
- Published
- 2021
3. A Semliki Forest virus vector engineered to express IFNα induces efficient elimination of established tumors
- Author
-
Quetglas, J I, Fioravanti, J, Ardaiz, N, Medina-Echeverz, J, Baraibar, I, Prieto, J, Smerdou, C, and Berraondo, P
- Published
- 2012
- Full Text
- View/download PDF
4. Immunological effects of gene transfer with the sushi domain of IL-15Rα and a chimeric protein consisting of IL-15 fused to apolipoprotein A-1: PS2-082
- Author
-
Ochoa, M. C., Fioravanti, J., Duitman, E. H., Medina-Echeverz, J., Palazon, A., Arina, A., Dubrot, J., Alfaro, C., Morales-Kastresana, A., Murillo, O., Hervas-Stubbs, S., Prieto, J., Berraondo, P., and Melero, I.
- Published
- 2011
- Full Text
- View/download PDF
5. Bounding interferon alpha to apolipoprotein A-I: A strategy to reduce hematological toxicity while enhancing immunostimulatory properties: PS1-078
- Author
-
Fioravanti, J., González, I., Medina-Echeverz, J., Larrea, E., Ardaiz, N., Aseguinolaza, González G., Prieto, J., and Berraondo, P.
- Published
- 2011
- Full Text
- View/download PDF
6. P04.02 A novel cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies
- Author
-
Hinterberger, M, primary, Medina-Echeverz, J, additional, Testori, M, additional, Geiger, M, additional, Giessel, R, additional, Bathke, B, additional, Kassub, R, additional, Gräbnitz, F, additional, Fiore, G, additional, Wennier, S, additional, Chaplin, P, additional, Suter, M, additional, Hochrein, H, additional, and Lauterbach, H, additional
- Published
- 2020
- Full Text
- View/download PDF
7. PS1-078. Bounding interferon alpha to apolipoprotein A-I: A strategy to reduce hematological toxicity while enhancing immunostimulatory properties
- Author
-
Fioravanti, J., primary, González, I., additional, Medina-Echeverz, J., additional, Larrea, E., additional, Ardaiz, N., additional, Aseguinolaza, G. González, additional, Prieto, J., additional, and Berraondo, P., additional
- Published
- 2011
- Full Text
- View/download PDF
8. PS2-082 Immunological effects of gene transfer with the sushi domain of IL-15Rα and a chimeric protein consisting of IL-15 fused to apolipoprotein A-1
- Author
-
Ochoa, M.C., primary, Fioravanti, J., additional, Duitman, E.H., additional, Medina-Echeverz, J., additional, Palazon, A., additional, Arina, A., additional, Dubrot, J., additional, Alfaro, C., additional, Morales-Kastresana, A., additional, Murillo, O., additional, Hervas-Stubbs, S., additional, Prieto, J., additional, Berraondo, P., additional, and Melero, I., additional
- Published
- 2011
- Full Text
- View/download PDF
9. A Semliki Forest virus vector engineered to express IFNα induces efficient elimination of established tumors
- Author
-
Quetglas, J I, primary, Fioravanti, J, additional, Ardaiz, N, additional, Medina-Echeverz, J, additional, Baraibar, I, additional, Prieto, J, additional, Smerdou, C, additional, and Berraondo, P, additional
- Published
- 2011
- Full Text
- View/download PDF
10. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice
- Author
-
Gonzalez-Aparicio, M., primary, Alzuguren, P., additional, Mauleon, I., additional, Medina-Echeverz, J., additional, Hervas-Stubbs, S., additional, Mancheno, U., additional, Berraondo, P., additional, Crettaz, J., additional, Gonzalez-Aseguinolaza, G., additional, Prieto, J., additional, and Hernandez-Alcoceba, R., additional
- Published
- 2010
- Full Text
- View/download PDF
11. PS2-082 Immunological effects of gene transfer with the sushi domain of IL-15R α and a chimeric protein consisting of IL-15 fused to apolipoprotein A-1
- Author
-
Ochoa, M.C., Fioravanti, J., Duitman, E.H., Medina-Echeverz, J., Palazon, A., Arina, A., Dubrot, J., Alfaro, C., Morales-Kastresana, A., Murillo, O., Hervas-Stubbs, S., Prieto, J., Berraondo, P., and Melero, I.
- Published
- 2011
- Full Text
- View/download PDF
12. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)
- Author
-
Alfaro C, Teijeira A, Oñate C, Perez G, Fernandez de Sanmamed M, Mp, Andueza, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, Garasa S, Jp, Fusco, Ma, Aznar, Inoges S, Medina-Echeverz J, Pedro Berraondo, Jl, Perez-Gracia, and Melero I
13. Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases
- Author
-
Medina-Echeverz, J. (José)
- Subjects
- Transforming growth factor beta, Liver tumor, Metastases, Antitumor therapy, High density lipoproteins (HDLs)
- Abstract
Transforming growth factor β (TGF-β) is a powerful promoter of cancer progression and a key target for antitumor therapy. As cancer cells exhibit active cholesterol metabolism, high density lipoproteins (HDLs) appear as an attractive delivery system for anticancer TGFβ-inhibitory molecules. We constructed a plasmid encoding a potent TGF-β-blocking peptide (P144) linked to apolipoprotein A-I (ApoA-I) through a flexible linker (pApoLinkerP144). The ApoLinkerP144 sequence was then incorporated into a hepatotropic adeno-associated vector (AAVApoLinkerP144). The aim was to induce hepatocytes to produce HDLs containing a modified ApoA-I capable of blocking TGF-β. We observed that transduction of the murine liver with pApoLinkerP144 led to the appearance of a fraction of circulating HDL containing the fusion protein. These HDLs were able to attenuate TGF-β signaling in the liver and to enhance IL-12 -mediated IFN-γ production. Treatment of liver metastasis of MC38 colorectal cancer with AAVApoLinkerP144 resulted in a significant reduction of tumor growth and enhanced expression of IFN-γ and GM-CSF in cancerous tissue. ApoLinkerP144 also delayed MC38 liver metastasis in Rag2-/-IL2rγ-/- immunodeficient mice. This effect was associated with downregulation of TGF-β target genes essential for metastatic niche conditioning. Finally, in a subset of ret transgenic mice, a model of aggressive spontaneous metastatic melanoma, AAVApoLinkerP144 delayed tumor growth in association with increased CD8+ T cell numbers in regional lymph nodes. In conclusion, modification of HDLs to transport TGF-β-blocking molecules is a novel and promising approach to inhibit the growth of liver metastases by immunological and non-immunological mechanisms.
- Published
- 2014
14. Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells
- Author
-
Medina-Echeverz, J. (José)
- Subjects
- Interleukin-12, Cyclophosphamide, Colorectal cancer, Inflammatory myeloid cells
- Abstract
Interleukin-12 immune stimulation lacks efficacy in established solid tumor models. Disruption of tumor microenvironment homeostasis by low-dose cyclophosphamide prior to interleukin-12 gene therapy led to CD8+ T cell-driven established tumor rejection. This only takes place when inflammatory myeloid cells infiltrate the tumor bed, and is crucial for the latter antitumor response.
- Published
- 2012
15. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis.
- Author
-
Bella Á, Arrizabalaga L, Di Trani CA, Gonzalez-Gomariz J, Gomar C, Russo-Cabrera JS, Olivera I, Cirella A, Fernandez-Sendin M, Alvarez M, Teijeira A, Atay C, Medina-Echeverz J, Hinterberger M, Hochrein H, Melero I, Berraondo P, and Aranda F
- Subjects
- Animals, Mice, Omentum, Vaccinia virus genetics, Luciferases, Interleukin-12 genetics, Peritoneal Neoplasms
- Abstract
Background: Peritoneal carcinomatosis is an advanced stage of cancer in which the disease has spread to the peritoneal cavity. In order to restore antitumor immunity subverted by tumor cells in this location, we evaluated intraperitoneal administrations of modified vaccinia virus Ankara (MVA) engineered to express single-chain interleukin 12 (scIL-12) to increase antitumor immune responses., Methods: MVA encoding scIL-12 (MVA.scIL-12) was evaluated against peritoneal carcinomatosis models based on intraperitoneal engraftment of tumor cells. CD8-mediated immune responses, elucidated antitumor efficacy, and safety were evaluated following intravenous, intratumoral, or intraperitoneal administration of the viral vector. The immune response was measured by ELISpot (enzyme-linked immunosorbent spot), RNA sequencing, flow cytometry, intravital microscopy, and depletion of lymphocyte subsets with monoclonal antibodies. Safety was assessed by body-weight follow-up and blood testing. Tissue tropism on intravenous or intraperitoneal administration was assessed by bioluminescence analysis using a reporter MVA encoding luciferase., Results: Intraperitoneal or locoregional administration, but not other routes of administration, resulted in a potent immune response characterized by increased levels of tumor-specific CD8
+ T lymphocytes with the ability to produce both interferon-γ and tumor necrosis factor-α. The antitumor immune response was detectable not only in the peritoneal cavity but also systemically. As a result of intraperitoneal treatment, a single administration of MVA.scIL-12 encoding scIL-12 completely eradicated MC38 tumors implanted in the peritoneal cavity and also protected cured mice from subsequent subcutaneous rechallenges. Bioluminescence imaging using an MVA encoding luciferase revealed that intraperitoneal administration targets transgene to the omentum. The omentum is considered a key tissue in immune protection of the peritoneal cavity. The safety profile of intraperitoneal administration was also better than that following intravenous administration since no weight loss or hematological toxicity was observed when the vector was locally delivered into the peritoneal cavity., Conclusion: Intraperitoneal administration of MVA vectors encoding scIL-12 targets the omentum, which is the tissue where peritoneal carcinomatosis usually begins. MVA.scIL-12 induces a potent tumor-specific immune response that often leads to the eradication of experimental tumors disseminated to the peritoneal cavity., Competing Interests: Competing interests: IM reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, CYTOMX, Incyte, MedImmune, Tusk, F-Star, Genmab, Molecular Partners, Alligator, Bioncotech, MSD, Merck Serono, Boehringer Ingelheim, AstraZeneca, Numab, Catalym, and Bayer, and research funding from Roche, BMS, Alligator, and Highlight Therapeutics. PB and FA received research funding from Bavarian Nordic. CA, JM-E (former), MH, and HH are employees of Bavarian Nordic. The rest of the authors have no conflict of interest to declare., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2023
- Full Text
- View/download PDF
16. Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.
- Author
-
Hinterberger M, Endt K, Bathke B, Habjan M, Heiseke A, Schweneker M, Von Rohrscheidt J, Atay C, Chaplin P, Kalla M, Hausmann J, Schmittwolf C, Lauterbach H, Volkmann A, Hochrein H, and Medina-Echeverz J
- Subjects
- Humans, Mice, Animals, CD40 Ligand genetics, CD8-Positive T-Lymphocytes, Antibodies, Neoplasm, Vaccinia virus genetics, Neoplasms drug therapy, Cancer Vaccines
- Abstract
The induction of antiviral innate immunity by systemic immunization with live virus can be employed to positively impact the response to therapeutic vaccination. We previously demonstrated that systemic immunization with a non-replicating MVA encoding CD40 ligand (CD40L) enhances innate immune cell activation and function, and triggers potent antitumor CD8
+ T cell responses in different murine tumor models. Antitumor efficacy was increased when combined with tumor targeting antibodies. Here we report the development of TAEK-VAC-HerBy (TVH), a first-in-class human tumor antibody enhanced killing (TAEK) vaccine based on the non-replicating MVA-BN viral vector. It encodes the membrane bound form of human CD40L, HER2 and the transcription factor Brachyury. TVH is designed for therapeutic use in HER2- or Brachyury-expressing cancer patients in combination with tumor targeting antibodies. To preclude possible oncogenic activities in infected cells and to prevent binding of vaccine-encoded HER2 by monoclonal antibodies trastuzumab and pertuzumab, genetic modifications of HER2 were introduced in the vaccine. Brachyury was genetically modified to prevent nuclear localization of the protein thereby inhibiting its transcriptional activity. CD40L encoded in TVH enhanced human leukocyte activation and cytokine secretion in vitro. Lastly, TVH intravenous administration to non-human primates was proven immunogenic and safe in a repeat-dose toxicity study. Nonclinical data presented here highlight TVH as a first-in-class immunotherapeutic vaccine platform currently under clinical investigation., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
17. Armored modified vaccinia Ankara in cancer immunotherapy.
- Author
-
Atay C, Medina-Echeverz J, Hochrein H, Suter M, and Hinterberger M
- Subjects
- Humans, Vaccinia virus genetics, Vaccination, Immunity, Innate, Vaccinia, Neoplasms therapy
- Abstract
Cancer immunotherapy relies on unleashing the patient´s immune system against tumor cells. Cancer vaccines aim to stimulate both the innate and adaptive arms of immunity to achieve durable clinical responses. Some roadblocks for a successful cancer vaccine in the clinic include the tumor antigen of choice, the adjuvants employed to strengthen antitumor-specific immune responses, and the risks associated with enhancing immune-related adverse effects in patients. Modified vaccinia Ankara (MVA) belongs to the family of poxviruses and is a versatile vaccine platform that combines several attributes crucial for cancer therapy. First, MVA is an excellent inducer of innate immune responses leading to type I interferon secretion and induction of T helper cell type 1 (Th1) immune responses. Second, it elicits robust and durable humoral and cellular immunity against vector-encoded heterologous antigens. Third, MVA has enormous genomic flexibility, which allows for the expression of multiple antigenic and costimulatory entities. And fourth, its replication deficit in human cells ensures a excellent safety profile. In this review, we summarize the current understanding of how MVA induces innate and adaptive immune responses. Furthermore, we will give an overview of the tumor-associated antigens and immunomodulatory molecules that have been used to armor MVA and describe their clinical use. Finally, the route of MVA immunization and its impact on therapeutic efficacy depending on the immunomodulatory molecules expressed will be discussed., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
18. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis.
- Author
-
Bella Á, Arrizabalaga L, Di Trani CA, Cirella A, Fernandez-Sendin M, Gomar C, Russo-Cabrera JS, Rodríguez I, González-Gomariz J, Alvarez M, Teijeira Á, Medina-Echeverz J, Hinterberger M, Hochrein H, Melero I, Berraondo P, and Aranda F
- Subjects
- Animals, CD40 Ligand genetics, Immunity, Mice, Vaccinia virus genetics, 4-1BB Ligand metabolism, Peritoneal Neoplasms therapy, Vaccinia
- Abstract
Recombinant-modified vaccinia virus Ankara (rMVA) is known to elicit potent antitumor immune responses in preclinical models due to its inherent ability to activate the innate immune system and the activation of adaptive responses mediated by the expression of tumor antigens and costimulus-providing molecules, such as CD40L and CD137L. Here, we evaluated different rMVA vectors in preclinical peritoneal carcinomatosis models (ID8.OVA- Vegf /GFP and MC38). We compared rMVA vectors expressing a tumor antigen (OVA or gp70) either alone or co-expressed with CD40L or/and CD137L. In tumor-free mice, the vector coding for the triple combination was only slightly superior, whereas, in tumor-bearing animals, we observed a synergistic induction of T lymphocytes specific against vector-encoded and non-encoded tumor-associated antigens. The enhanced activation of the immune response was associated with improved survival in mice with peritoneal carcinomatosis treated with a rMVA vector encoding both CD40L and CD137L. Thus, the triple transgene combination in vaccinia viral vectors represents a promising strategy for the treatment of peritoneal carcinomatosis., (© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.)
- Published
- 2022
- Full Text
- View/download PDF
19. CD137 (4-1BB) costimulation of CD8 + T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation.
- Author
-
Otano I, Azpilikueta A, Glez-Vaz J, Alvarez M, Medina-Echeverz J, Cortés-Domínguez I, Ortiz-de-Solorzano C, Ellmark P, Fritzell S, Hernandez-Hoyos G, Nelson MH, Ochoa MC, Bolaños E, Cuculescu D, Jaúregui P, Sanchez-Gregorio S, Etxeberria I, Rodriguez-Ruiz ME, Sanmamed MF, Teijeira Á, Berraondo P, and Melero I
- Subjects
- Animals, CD3 Complex genetics, Cell Proliferation, Cytokines genetics, Cytokines immunology, Humans, Lymphocyte Activation, Mice, Mice, Inbred C57BL, Receptor-CD3 Complex, Antigen, T-Cell genetics, Tumor Necrosis Factor Receptor Superfamily, Member 9 genetics, CD3 Complex immunology, CD8-Positive T-Lymphocytes immunology, Receptor-CD3 Complex, Antigen, T-Cell immunology, Tumor Necrosis Factor Receptor Superfamily, Member 9 immunology
- Abstract
CD137 (4-1BB; TNFSR9) is an activation-induced surface receptor that through costimulation effects provide antigen-primed T cells with augmented survival, proliferation and effector functions as well as metabolic advantages. These immunobiological mechanisms are being utilised for cancer immunotherapy with agonist CD137-binding and crosslinking-inducing agents that elicit CD137 intracellular signaling. In this study, side-by-side comparisons show that provision of CD137 costimulation in-cis with regard to the TCR-CD3-ligating cell is superior to that provided in-trans in terms of T cell activation, proliferation, survival, cytokine secretion and mitochondrial fitness in mouse and human. Cis ligation of CD137 relative to the TCR-CD3 complex results in more intense canonical and non-canonical NF-κB signaling and provides a more robust induction of cell cycle and DNA damage repair gene expression programs. Here we report that the superiority of cis versus trans CD137-costimulation is readily observed in vivo and is relevant for understanding the immunotherapeutic effects of CAR T cells and CD137 agonistic therapies currently undergoing clinical trials, which may provide costimulation either in cis or in trans., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
20. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.
- Author
-
Tenesaca S, Vasquez M, Alvarez M, Otano I, Fernandez-Sendin M, Di Trani CA, Ardaiz N, Gomar C, Bella A, Aranda F, Medina-Echeverz J, Melero I, and Berraondo P
- Subjects
- Animals, Cancer Vaccines pharmacology, Disease Models, Animal, Female, Genetic Vectors pharmacology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Mice, Cancer Vaccines therapeutic use, Genetic Vectors therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Interferon Type I antagonists & inhibitors, Vaccinia virus drug effects
- Abstract
Background: Modified vaccinia virus Ankara (MVA) are genetically engineered non-replicating viral vectors. Intratumoral administration of MVA induces a cyclic GMP-AMP synthase-mediated type I interferon (IFN) response and the production of high levels of the transgenes engineered into the viral genome such as tumor antigens to construct cancer vaccines. Although type I IFNs are essential for establishing CD8-mediated antitumor responses, this cytokine family may also give rise to immunosuppressive mechanisms., Methods: In vitro assays were performed to evaluate the activity of simvastatin and atorvastatin on type I IFN signaling and on antigen presentation. Surface levels of IFN α/β receptor 1, endocytosis of bovine serum albumin-fluorescein 5 (6)-isothiocyanate, signal transducer and activator of transcription (STAT) phosphorylation, and real-time PCR of IFN-stimulated genes were assessed in the murine fibroblast cell line L929. In vivo experiments were performed to characterize the effect of simvastatin on the MVA-induced innate immune response and on the antitumor effect of MVA-based antitumor vaccines in B16 melanoma expressing ovalbumin (OVA) and Lewis lung carcinoma (LLC)-OVA tumor models. RNAseq analysis, depleting monoclonal antibodies, and flow cytometry were used to evaluate the MVA-mediated immune response., Results: In this work, we identified commonly prescribed statins as potent IFNα pharmacological inhibitors due to their ability to reduce surface expression levels of IFN-α/β receptor 1 and to reduce clathrin-mediated endocytosis. Simvastatin and atorvastatin efficiently abrogated for 8 hours the transcriptomic response to IFNα and enhanced the number of dendritic cells presenting an OVA-derived peptide bound to major histocompatibility complex (MHC) class I. In vivo, intraperitoneal or intramuscular administration of simvastatin reduced the inflammatory response mediated by peritumoral administration of MVA and enhanced the antitumor activity of MVA encoding tumor-associated antigens. The synergistic antitumor effects critically depend on CD8
+ cells, whereas they were markedly improved by depletion of CD4+ lymphocytes, T regulatory cells, or NK cells. Either MVA-OVA alone or combined with simvastatin augmented B cells, CD4+ lymphocytes, CD8+ lymphocytes, and tumor-specific CD8+ in the tumor-draining lymph nodes. However, only the treatment combination increased the numbers of these lymphocyte populations in the tumor microenvironment and in the spleen., Conclusion: In conclusion, blockade of IFNα functions by simvastatin markedly enhances lymphocyte infiltration and the antitumor activity of MVA, prompting a feasible drug repurposing., Competing Interests: Competing interests: IM reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, CYTOMX, Incyte, MedImmune, Tusk, F-Star, Genmab, Molecular Partners, Alligator, Bioncotech, MSD, Merck Serono, Boehringer Ingelheim, Astra Zeneca, Numab, Catalym, Bayer and PharmaMar, and research funding from Roche, BMS, Alligator and Bioncotech. PB reports advisory roles with Ferring, Tusk and Moderna, research funding from Sanofi, Ferring, and Bavarian Nordic and speaker honoraria from BMS, MSD, Novartis, Boehringer Ingelheim, and AstraZeneca. JM-E is an employee of Bavarian Nordic. The rest of the authors have no conflict of interest to declare., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF
21. Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications.
- Author
-
Bella Á, Di Trani CA, Fernández-Sendin M, Arrizabalaga L, Cirella A, Teijeira Á, Medina-Echeverz J, Melero I, Berraondo P, and Aranda F
- Abstract
Peritoneal carcinomatosis of primary tumors originating in gastrointestinal (e.g., colorectal cancer, gastric cancer) or gynecologic (e.g., ovarian cancer) malignancies is a widespread type of tumor dissemination in the peritoneal cavity for which few therapeutic options are available. Therefore, reliable preclinical models are crucial for research and development of efficacious treatments for this condition. To date, a number of animal models have attempted to reproduce as accurately as possible the complexity of the tumor microenvironment of human peritoneal carcinomatosis. These include: Syngeneic tumor cell lines, human xenografts, patient-derived xenografts, genetically induced tumors, and 3D scaffold biomimetics. Each experimental model has its own strengths and limitations, all of which can influence the subsequent translational results concerning anticancer and immunomodulatory drugs under exploration. This review highlights the current status of peritoneal carcinomatosis mouse models for preclinical development of anticancer drugs or immunotherapeutic agents.
- Published
- 2021
- Full Text
- View/download PDF
22. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
- Author
-
Hinterberger M, Giessel R, Fiore G, Graebnitz F, Bathke B, Wennier S, Chaplin P, Melero I, Suter M, Lauterbach H, Berraondo P, Hochrein H, and Medina-Echeverz J
- Subjects
- 4-1BB Ligand metabolism, Animals, Antigens, Neoplasm metabolism, CD8-Positive T-Lymphocytes metabolism, Cell Line, Tumor, Cloning, Molecular, Combined Modality Therapy, Drug Synergism, Female, Immunologic Memory, Melanoma, Experimental immunology, Mice, Treatment Outcome, Tumor Microenvironment, Vaccinia virus genetics, 4-1BB Ligand genetics, Antigens, Neoplasm genetics, Melanoma, Experimental therapy, Oncolytic Virotherapy methods, Vaccinia virus physiology
- Abstract
Background Human cancers are extraordinarily heterogeneous in terms of tumor antigen expression, immune infiltration and composition. A common feature, however, is the host's inability to mount potent immune responses that prevent tumor growth effectively. Often, naturally primed CD8
+ T cells against solid tumors lack adequate stimulation and efficient tumor tissue penetration due to an immune hostile tumor microenvironment. Methods To address these shortcomings, we cloned tumor-associated antigens (TAA) and the immune-stimulatory ligand 4-1BBL into the genome of modified vaccinia Ankara (MVA) for intratumoral virotherapy. Results Local treatment with MVA-TAA-4-1BBL resulted in control of established tumors. Intratumoral injection of MVA localized mainly to the tumor with minimal leakage to the tumor-draining lymph node. In situ infection by MVA-TAA-4-1BBL triggered profound changes in the tumor microenvironment, including the induction of multiple proinflammatory molecules and immunogenic cell death. These changes led to the reactivation and expansion of antigen-experienced, tumor-specific cytotoxic CD8+ T cells that were essential for the therapeutic antitumor effect. Strikingly, we report the induction of a systemic antitumor immune response including tumor antigen spread by local MVA-TAA-4-1BBL treatment which controlled tumor growth at distant, untreated lesions and protected against local and systemic tumor rechallenge. In all cases, 4-1BBL adjuvanted MVA was superior to MVA. Conclusion Intratumoral 4-1BBL-armed MVA immunotherapy induced a profound reactivation and expansion of potent tumor-specific CD8+ T cells as well as favorable proinflammatory changes in the tumor microenvironment, leading to elimination of tumors and protective immunological memory., Competing Interests: Competing interests: MH, RG, FG, GF, BB, SW, PC, MS, HL, HH and JM-E are or have been employees of Bavarian Nordic. IM reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, CYTOMX, Incyte, MedImmune, Tusk, F-Star, Genmab, Molecular Partners, Alligator, Bioncotech, MSD, Merck Serono, Boehringer Ingelheim, Astra Zeneca, Numab, Catalym, Bayer, and PharmaMar, and research funding from Roche, BMS, Alligator, and Bioncotech. PB reports advisory roles with Ferring, Tusk and Moderna, research funding from Sanofi, and Bavarian Nordic and speaker honoraria from Ferring, BMS, MSD, Novartis, Boehringer Ingelheim and AstraZeneca., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF
23. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
- Author
-
Medina-Echeverz J, Hinterberger M, Testori M, Geiger M, Giessel R, Bathke B, Kassub R, Gräbnitz F, Fiore G, Wennier ST, Chaplin P, Suter M, Hochrein H, and Lauterbach H
- Subjects
- Adjuvants, Immunologic therapeutic use, Animals, Antineoplastic Agents therapeutic use, CD8-Positive T-Lymphocytes immunology, Cell Line, Tumor, Drug Synergism, Female, Humans, Immunization, Killer Cells, Natural immunology, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms immunology, Vaccination, Vaccines, Synthetic immunology, Vaccines, Synthetic therapeutic use, Adaptive Immunity, Antibodies, Neoplasm immunology, CD40 Ligand pharmacology, Cancer Vaccines immunology, Immunity, Innate, Immunotherapy methods, Neoplasms therapy, Viral Vaccines therapeutic use
- Abstract
Virus-based vaccines and appropriate costimulation potently enhance antigen-specific T cell immunity against cancer. Here we report the use of recombinant modified vaccinia virus Ankara (rMVA) encoding costimulatory CD40L against solid tumors. Therapeutic treatment with rMVA-CD40L-expressing tumor-associated antigens results in the control of established tumors. The expansion of tumor-specific cytotoxic CD8
+ T cells is essential for the therapeutic antitumor effects. Strikingly, rMVA-CD40L also induces strong natural killer (NK) cell activation and expansion. Moreover, the combination of rMVA-CD40L and tumor-targeting antibodies results in increased therapeutic antitumor efficacy relying on the presence of Fc receptor and NK cells. We describe a translationally relevant therapeutic synergy between systemic viral vaccination and CD40L costimulation. We show strengthened antitumor immune responses when both rMVA-CD40L-induced innate and adaptive immune mechanisms are exploited by combination with tumor-targeting antibodies. This immunotherapeutic approach could translate into clinical cancer therapies where tumor-targeting antibodies are employed.- Published
- 2019
- Full Text
- View/download PDF
24. Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression.
- Author
-
Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M, Wang XW, Zender L, and Greten TF
- Subjects
- Animals, Carcinoma, Hepatocellular pathology, Cellular Senescence immunology, Disease Progression, Female, Humans, Immunologic Surveillance, Liver Neoplasms pathology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Carcinoma, Hepatocellular immunology, Liver Neoplasms immunology
- Abstract
Oncogene-induced senescence causes hepatocytes to secrete cytokines, which induce their immune-mediated clearance to prevent tumor initiation, a process termed "senescence surveillance." However, senescent hepatocytes give rise to hepatocellular carcinomas (HCCs), if the senescence program is bypassed or if senescent cells are not cleared. Here, we show context-specific roles for CCR2
+ myeloid cells in liver cancer. Senescence surveillance requires the recruitment and maturation of CCR2+ myeloid cells, and CCR2 ablation caused outgrowth of HCC. In contrast, HCC cells block the maturation of recruited myeloid precursors, which, through NK cell inhibition, promote growth of murine HCC and worsen the prognosis and survival of human HCC patients. Thus, while senescent hepatocyte-secreted chemokines suppress liver cancer initiation, they may accelerate the growth of fully established HCC., (Published by Elsevier Inc.)- Published
- 2016
- Full Text
- View/download PDF
25. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
- Author
-
Venugopalan A, Lee MJ, Niu G, Medina-Echeverz J, Tomita Y, Lizak MJ, Cultraro CM, Simpson RM, Chen X, Trepel JB, and Guha U
- Subjects
- Adenocarcinoma diagnostic imaging, Adenocarcinoma genetics, Adenocarcinoma pathology, Adenocarcinoma of Lung, Animals, Apoptosis drug effects, Cetuximab therapeutic use, ErbB Receptors genetics, ErbB Receptors physiology, Erlotinib Hydrochloride therapeutic use, Humans, Lung Neoplasms diagnostic imaging, Lung Neoplasms genetics, Lung Neoplasms pathology, Mice, Positron-Emission Tomography, Xenograft Model Antitumor Assays, Adenocarcinoma drug therapy, ErbB Receptors antagonists & inhibitors, Lung Neoplasms drug therapy, Mutation, Protein Kinase Inhibitors therapeutic use
- Abstract
Lung adenocarcinoma patients harboring kinase domain mutations in Epidermal growth factor receptor (EGFR) have significant clinical benefit from EGFR-targeted tyrosine kinase inhibitors (TKIs). Although a majority of patients experience clinical symptomatic benefit immediately, an objective response can only be demonstrated after 6-8 weeks of treatment. Evaluation of patient response by imaging shows that 30-40% of patients do not respond due to intrinsic resistance to these TKIs. We investigated immediate-early effects of EGFR-TKI treatment in mutant EGFR-driven transgenic mouse models by FDG-PET and MRI and correlated the effects on the tumor and the tumor microenvironment. Within 24 hours of erlotinib treatment we saw approximately 65% tumor regression in mice with TKI-sensitive EGFRL858R lung adenocarcinoma. However, mice with EGFRL858R/T790M-driven tumors did not respond to either erlotinib or afatinib monotherapy, but did show a significant tumor response to afatinib-cetuximab combination treatment. The imaging responses correlated with the inhibition of downstream EGFR signaling, increased apoptosis, and decreased proliferation in the tumor tissues. In EGFRL858R-driven tumors, we saw a significant increase in CD45+ leukocytes, NK cells, dendritic cells, macrophages and lymphocytes, particularly CD8+ T cells. In response to erlotinib, these dendritic cells and macrophages had significantly higher MHC class II expression, indicating increased antigen-presenting capabilities. Together, results of our study provide novel insight into the immediate-early therapeutic response to EGFR TKIs in vivo.
- Published
- 2016
- Full Text
- View/download PDF
26. Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).
- Author
-
Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, Garasa S, Fusco JP, Aznar A, Inogés S, De Pizzol M, Allegretti M, Medina-Echeverz J, Berraondo P, Perez-Gracia JL, and Melero I
- Subjects
- Animals, Biomarkers, Cell Line, Tumor, Chemotaxis, Leukocyte drug effects, Disease Models, Animal, Humans, Interleukin-8 pharmacology, Mice, Mice, Knockout, Myeloid-Derived Suppressor Cells drug effects, Neoplasms immunology, Neoplasms metabolism, Neoplasms pathology, Sulfonamides pharmacology, T-Lymphocyte Subsets drug effects, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, Chemotaxis, Leukocyte immunology, Extracellular Traps immunology, Interleukin-8 metabolism, Myeloid-Derived Suppressor Cells immunology, Myeloid-Derived Suppressor Cells metabolism, Neutrophils immunology
- Abstract
Purpose: Myeloid-derived suppressor cells (MDSC) are considered an important T-cell immunosuppressive component in cancer-bearing hosts. The factors that attract these cells to the tumor microenvironment are poorly understood. IL8 (CXCL8) is a potent chemotactic factor for neutrophils and monocytes., Experimental Design: MDSC were characterized and sorted by multicolor flow cytometry on ficoll-gradient isolated blood leucokytes from healthy volunteers (n = 10) and advanced cancer patients (n = 28). In chemotaxis assays, sorted granulocytic and monocytic MDSC were tested in response to recombinant IL8, IL8 derived from cancer cell lines, and patient sera. Neutrophil extracellular traps (NETs) formation was assessed by confocal microscopy, fluorimetry, and time-lapse fluorescence confocal microscopy on short-term MDSC cultures., Results: IL8 chemoattracts both granulocytic (GrMDSC) and monocytic (MoMDSC) human MDSC. Monocytic but not granulocytic MDSC exerted a suppressor activity on the proliferation of autologous T cells isolated from the circulation of cancer patients. IL8 did not modify the T-cell suppressor activity of human MDSC. However, IL8 induced the formation of NETs in the GrMDSC subset., Conclusions: IL8 derived from tumors contributes to the chemotactic recruitment of MDSC and to their functional control. Clin Cancer Res; 22(15); 3924-36. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
27. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.
- Author
-
Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, McVicar DW, Weber A, Heikenwalder M, and Greten TF
- Subjects
- Animals, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes pathology, Carcinoma, Hepatocellular metabolism, Case-Control Studies, Choline metabolism, Diet, Disease Models, Animal, Genes, myc, Hepatocytes metabolism, Hepatocytes pathology, Humans, Linoleic Acid metabolism, Lipid Metabolism, Liver immunology, Liver pathology, Liver Neoplasms metabolism, Male, Methionine deficiency, Mice, Mice, Inbred C57BL, Mitochondria metabolism, Mitochondria pathology, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease pathology, Oxidative Stress, Reactive Oxygen Species metabolism, CD4-Positive T-Lymphocytes pathology, Carcinogenesis immunology, Carcinogenesis pathology, Carcinoma, Hepatocellular immunology, Carcinoma, Hepatocellular pathology, Liver Neoplasms immunology, Liver Neoplasms pathology, Non-alcoholic Fatty Liver Disease immunology
- Abstract
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the US population and is considered to be a metabolic predisposition to liver cancer. However, the role of adaptive immune responses in NAFLD-promoted HCC is largely unknown. Here we show, in mouse models and human samples, that dysregulation of lipid metabolism in NAFLD causes a selective loss of intrahepatic CD4(+) but not CD8(+) T lymphocytes, leading to accelerated hepatocarcinogenesis. We also demonstrate that CD4(+) T lymphocytes have greater mitochondrial mass than CD8(+) T lymphocytes and generate higher levels of mitochondrially derived reactive oxygen species (ROS). Disruption of mitochondrial function by linoleic acid, a fatty acid accumulated in NAFLD, causes more oxidative damage than other free fatty acids such as palmitic acid, and mediates selective loss of intrahepatic CD4(+) T lymphocytes. In vivo blockade of ROS reversed NAFLD-induced hepatic CD4(+) T lymphocyte decrease and delayed NAFLD-promoted HCC. Our results provide an unexpected link between lipid dysregulation and impaired anti-tumour surveillance.
- Published
- 2016
- Full Text
- View/download PDF
28. Hepatic myeloid-derived suppressor cells in cancer.
- Author
-
Medina-Echeverz J, Eggert T, Han M, and Greten TF
- Subjects
- Animals, Carcinoma, Hepatocellular pathology, Humans, Liver immunology, Liver pathology, Liver Neoplasms pathology, Myeloid Cells pathology, Neoplasm Metastasis, Tumor Escape, Carcinoma, Hepatocellular immunology, Immune Tolerance, Immunosuppression Therapy, Liver Neoplasms immunology, Myeloid Cells immunology
- Abstract
Myeloid-derived suppressor cells are key components of tumor-induced immune suppression. They are composed of a heterogeneous population of immature myeloid cells that abrogates innate and adaptive immune responses. Myeloid-derived suppressor cells accumulate not only in peripheral blood, secondary lymphoid organs and tumors, but also in the liver in preclinical tumor models and in hepatocellular carcinoma patients. The liver, continuously exposed to food and microbial antigens from the intestine, avoids autoimmune damage through the use of specialized mechanisms of immune tolerance. In the context of cancer, myeloid-derived suppressor cells profit the intrinsic tolerogenic properties of the liver to accumulate and exert various immune-suppressive and tumor-promoting mechanisms which go from inducing immune cell dysfunction to supporting the generation of liver metastases. In this review, we seek to describe the phenotype, function, accumulation and therapeutic targeting of hepatic myeloid-derived suppressor cells both in preclinical settings and in the context of human hepatocellular carcinoma.
- Published
- 2015
- Full Text
- View/download PDF
29. Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.
- Author
-
Medina-Echeverz J, Vasquez M, Gomar C, Ardaiz N, and Berraondo P
- Subjects
- Animals, Apolipoprotein A-I genetics, Apolipoprotein A-I immunology, Cell Line, Tumor, Colonic Neoplasms genetics, Colonic Neoplasms immunology, Colonic Neoplasms pathology, Female, Genetic Therapy, Immunotherapy, Mice, Mice, Inbred C57BL, Mice, Knockout, Peptide Fragments genetics, Peptide Fragments immunology, Receptors, Transforming Growth Factor beta genetics, Receptors, Transforming Growth Factor beta immunology, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins immunology, Transfection, Transforming Growth Factor beta metabolism, Tumor Cells, Cultured, Apolipoprotein A-I biosynthesis, Colonic Neoplasms therapy, Peptide Fragments biosynthesis, Receptors, Transforming Growth Factor beta biosynthesis, Recombinant Fusion Proteins biosynthesis, Transforming Growth Factor beta antagonists & inhibitors
- Abstract
Transforming growth factor beta (TGF-β) promotes tumor growth, invasion and metastasis in established tumors. In this study, we analyzed the effect of overexpressing an anti-TGF-β peptide fused to apolipoprotein A-I (ApoA-I) as a scaffold molecule. We generated and characterized stable MC38 colon carcinoma clones expressing ApoA-I fused to the anti-TGF-β peptide P144 and ApoA-I as control cells. We evaluated in vitro the gene expression profile, cell cycle and anchorage-independent growth. The in vivo tumorigenic potential and immunogenicity were analyzed inoculating the MC38 clones into C57BL/6 mice, recombination-activating gene 1 knockout mice or mice deficient in NK cells either subcutaneously or intrasplenically to generate hepatic metastases. While overexpression of ApoA-I had no effect on the parameters analyzed, ApoA-I fused to P144 markedly diminished the tumorigenic capacity and metastatic potential of MC38 in vitro and in vivo, thus generating a highly immunogenic cell line. MC38 cells transfected with ApoA-I fused to P144 triggered memory T cell responses able to eliminate the parental cell line upon re-challenge. In summary, expression of ApoA-I fused to P144 is a novel strategy to modulate TGF-β in tumor cells. These results highlight the potential of TGF-β as a target in the development of new antitumor treatments.
- Published
- 2015
- Full Text
- View/download PDF
30. The yin and yang of evasion and immune activation in HCC.
- Author
-
Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, and Greten TF
- Subjects
- Adoptive Transfer, Cancer Vaccines therapeutic use, Clinical Trials as Topic, Cytokines therapeutic use, Humans, Immune Tolerance, Immunosuppression Therapy, Carcinoma, Hepatocellular immunology, Carcinoma, Hepatocellular therapy, Immunotherapy methods, Liver Neoplasms immunology, Liver Neoplasms therapy
- Abstract
Current systemic treatment options for patients with hepatocellular carcinoma (HCC) are limited to sorafenib. With the recent FDA approval of the second PD1-PD-L1 pathway inhibitor, immunotherapy has gained even more interest as a potential novel treatment option for patients with HCC. This is due not only because of the failure of other treatment approaches in the past, but also because immunological mechanisms have been shown to play an important role during tumor development, growth, and treatment. Here we present a review of immunological mechanisms in the liver relevant for tumor progression and treatment. We summarize our current knowledge on immune activating and immune suppressing mechanisms during tumor initiation, development, and treatment. We try to explain the paradox of how inflammatory responses in a setting of chronic infection promote tumor development, while the primary aim of immunotherapy is to activate immunity. Finally we summarize recent advances in addition to providing an outlook for the immunotherapy of HCC., (Published by Elsevier B.V.)
- Published
- 2015
- Full Text
- View/download PDF
31. Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.
- Author
-
Medina-Echeverz J, Ma C, Duffy AG, Eggert T, Hawk N, Kleiner DE, Korangy F, and Greten TF
- Subjects
- Alanine Transaminase blood, Animals, Aspartate Aminotransferases blood, CD40 Antigens immunology, Cell Line, Tumor, Chemical and Drug Induced Liver Injury blood, Chemical and Drug Induced Liver Injury immunology, Female, Humans, Liver cytology, Liver drug effects, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Myeloid Cells immunology, Neoplasms blood, Neoplasms drug therapy, Neoplasms immunology, Spleen cytology, Spleen drug effects, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal therapeutic use, CD40 Antigens antagonists & inhibitors, Myeloid Cells drug effects
- Abstract
Immune-stimulatory mAbs are currently being evaluated as antitumor agents. Although overall toxicity from these agents appears to be moderate, liver toxicities have been reported and are not completely understood. We studied the effect of systemic CD40 antibody treatment on myeloid cells in the spleen and liver. Naïve and tumor-bearing mice were treated systemically with agonistic anti-CD40 antibody. Immune cell subsets in the liver and spleen, serum transaminases, and liver histologies were analyzed after antibody administration. Nox2(-/-), Cd40(-/-), and bone marrow chimeric mice were used to study the mechanism by which agonistic anti-CD40 mediates its effects in vivo. Suppressor function of murine and human tumor-induced myeloid-derived suppressor cells (MDSC) was studied upon CD40 ligation. Agonistic CD40 antibody caused liver damage within 24 hours after injection in two unrelated tumor models and mice strains. Using bone marrow chimeras, we demonstrate that CD40 antibody-induced hepatitis in tumor-bearing mice was dependent on the presence of CD40-expressing hematopoietic cells. Agonistic CD40 ligation-dependent liver damage was induced by the generation of reactive oxygen species. Furthermore, agonistic CD40 antibody resulted in increased CD80-positive and CD40-positive liver CD11b(+)Gr-1(+) immature myeloid cells. CD40 ligation on tumor-induced murine and human CD14(+)HLA-DR(low) peripheral blood mononuclear cells from patients with cancer reduced their immune suppressor function. Collectively, agonistic CD40 antibody treatment activated tumor-induced myeloid cells, caused myeloid-dependent hepatotoxicity, and ameliorated the suppressor function of murine and human MDSC. Collectively, our data suggest that CD40 may mature immunosuppressive myeloid cells and thereby cause liver damage in mice with an accumulation of tumor-induced hepatic MDSC., (©2015 American Association for Cancer Research.)
- Published
- 2015
- Full Text
- View/download PDF
32. Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.
- Author
-
Kapanadze T, Medina-Echeverz J, Gamrekelashvili J, Weiss JM, Wiltrout RH, Kapoor V, Hawk N, Terabe M, Berzofsky JA, Manns MP, Wang E, Marincola FM, Korangy F, and Greten TF
- Subjects
- Adoptive Transfer, Alanine Transaminase blood, Animals, Antigens, CD1d biosynthesis, Arginase antagonists & inhibitors, Arginase biosynthesis, Arginase metabolism, Aspartate Aminotransferases blood, B7-1 Antigen biosynthesis, B7-2 Antigen biosynthesis, CD11b Antigen metabolism, CD40 Antigens biosynthesis, CD40 Antigens genetics, Cell Line, Concanavalin A pharmacology, Female, Galactosylceramides pharmacology, Hepatitis genetics, Hepatocytes immunology, Hepatocytes pathology, Liver cytology, Liver injuries, Liver Neoplasms immunology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Mitogens pharmacology, Myeloid Cells transplantation, Reactive Oxygen Species metabolism, Receptors, Chemokine metabolism, CD40 Antigens metabolism, Hepatitis immunology, Myeloid Cells immunology
- Abstract
Immunosuppressive CD11b(+) Gr-1(+) myeloid-derived suppressor cells (MDSCs) accumulate in the livers of tumor-bearing (TB) mice. We studied hepatic MDSCs in two murine models of immune-mediated hepatitis. Unexpectedly, treatment of TB mice with Concanavalin A (Con A) or α-galactosylceramide resulted in increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serum levels in comparison to tumor-free mice. Adoptive transfer of hepatic MDSCs into naïve mice exacerbated Con A induced liver damage. Hepatic CD11b(+) Gr-1(+) cells revealed a polarized proinflammatory gene signature after Con A treatment. An IFN-γ-dependent upregulation of CD40 on hepatic CD11b(+) Gr-1(+) cells along with an upregulation of CD80, CD86, and CD1d after Con A treatment was observed. Con A treatment resulted in a loss of suppressor function by tumor-induced CD11b(+) Gr-1(+) MDSCs as well as enhanced reactive oxygen species (ROS)-mediated hepatotoxicity. CD40 knockdown in hepatic MDSCs led to increased arginase activity upon Con A treatment and lower ALT/AST serum levels. Finally, blockade of arginase activity in Cd40(-/-) tumor-induced myeloid cells resulted in exacerbation of hepatitis and increased ROS production in vivo. Our findings indicate that in a setting of acute hepatitis, tumor-induced hepatic MDSCs act as proinflammatory immune effector cells capable of killing hepatocytes in a CD40-dependent manner., (Published 2015. This article is a U.S. Government work and is in the public domain in the USA.)
- Published
- 2015
- Full Text
- View/download PDF
33. Tumor induced hepatic myeloid derived suppressor cells can cause moderate liver damage.
- Author
-
Eggert T, Medina-Echeverz J, Kapanadze T, Kruhlak MJ, Korangy F, and Greten TF
- Subjects
- Animals, Antigens, Surface metabolism, Cell Line, Tumor, Cytokines metabolism, Disease Models, Animal, Female, Immunophenotyping, Liver metabolism, Melanoma, Experimental, Mice, Myeloid Cells metabolism, Neoplasms blood, Neoplasms metabolism, Phenotype, Transaminases blood, Liver immunology, Liver pathology, Myeloid Cells immunology, Neoplasms immunology
- Abstract
Subcutaneous tumors induce the accumulation of myeloid derived suppressor cells (MDSC) not only in blood and spleens, but also in livers of these animals. Unexpectedly, we observed a moderate increase in serum transaminases in mice with EL4 subcutaneous tumors, which prompted us to study the relationship of hepatic MDSC accumulation and liver injury. MDSC were the predominant immune cell population expanding in livers of all subcutaneous tumor models investigated (RIL175, B16, EL4, CT26 and BNL), while liver injury was only observed in EL4 and B16 tumor-bearing mice. Elimination of hepatic MDSC in EL4 tumor-bearing mice using low dose 5-fluorouracil (5-FU) treatment reversed transaminase elevation and adoptive transfer of hepatic MDSC from B16 tumor-bearing mice caused transaminase elevation indicating a direct MDSC mediated effect. Surprisingly, hepatic MDSC from B16 tumor-bearing mice partially lost their damage-inducing potency when transferred into mice bearing non damage-inducing RIL175 tumors. Furthermore, MDSC expansion and MDSC-mediated liver injury further increased with growing tumor burden and was associated with different cytokines including GM-CSF, VEGF, interleukin-6, CCL2 and KC, depending on the tumor model used. In contrast to previous findings, which have implicated MDSC only in protection from T cell-mediated hepatitis, we show that tumor-induced hepatic MDSC themselves can cause moderate liver damage.
- Published
- 2014
- Full Text
- View/download PDF
34. Intravenous immunoglobulin promotes antitumor responses by modulating macrophage polarization.
- Author
-
Domínguez-Soto A, de las Casas-Engel M, Bragado R, Medina-Echeverz J, Aragoneses-Fenoll L, Martín-Gayo E, van Rooijen N, Berraondo P, Toribio ML, Moro MA, Cuartero I, Castrillo A, Sancho D, Sánchez-Torres C, Bruhns P, Sánchez-Ramón S, and Corbí AL
- Subjects
- Animals, Cell Differentiation drug effects, Cell Differentiation immunology, Cells, Cultured, Cytokines genetics, Cytokines immunology, Humans, Lung drug effects, Lung immunology, Lung pathology, Lung Neoplasms genetics, Lung Neoplasms immunology, Lung Neoplasms pathology, Macrophages classification, Macrophages immunology, Macrophages pathology, Melanoma, Experimental genetics, Melanoma, Experimental immunology, Melanoma, Experimental pathology, Mice, Neoplasm Transplantation, Receptors, IgE genetics, Receptors, IgE immunology, Receptors, IgG genetics, Receptors, IgG immunology, Signal Transduction, Tumor Burden drug effects, Antineoplastic Agents pharmacology, Gene Expression Regulation, Neoplastic, Immunoglobulins, Intravenous pharmacology, Immunologic Factors pharmacology, Lung Neoplasms drug therapy, Macrophages drug effects, Melanoma, Experimental drug therapy
- Abstract
Intravenous Igs (IVIg) therapy is widely used as an immunomodulatory strategy in inflammatory pathologies and is suggested to promote cancer regression. Because progression of tumors depends on their ability to redirect the polarization state of tumor-associated macrophages (from M1/immunogenic/proinflammatory to M2/anti-inflammatory), we have evaluated whether IVIg limits tumor progression and dissemination through modulation of macrophage polarization. In vitro, IVIg inhibited proinflammatory cytokine production from M1 macrophages and induced a M2-to-M1 polarization switch on human and murine M2 macrophages. In vivo, IVIg modified the polarization of tumor-associated myeloid cells in a Fcεr1γ chain-dependent manner, modulated cytokine blood levels in tumor-bearing animals, and impaired tumor progression via FcγRIII (CD16), FcγRIV, and FcRγ engagement, the latter two effects being macrophage mediated. Therefore, IVIg immunomodulatory activity is dependent on the polarization state of the responding macrophages, and its ability to trigger a M2-to-M1 macrophage polarization switch might be therapeutically useful in cancer, in which proinflammatory or immunogenic functions should be promoted., (Copyright © 2014 by The American Association of Immunologists, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
35. IFN-γ regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1.
- Author
-
Medina-Echeverz J, Haile LA, Zhao F, Gamrekelashvili J, Ma C, Métais JY, Dunbar CE, Kapoor V, Manns MP, Korangy F, and Greten TF
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, Cell Line, Female, Granulocyte-Macrophage Colony-Stimulating Factor immunology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Minor Histocompatibility Antigens, STAT1 Transcription Factor immunology, Up-Regulation immunology, Apoptosis immunology, CD11b Antigen immunology, Interferon-gamma immunology, Myeloid Cells immunology, Proto-Oncogene Proteins c-bcl-2 immunology, Receptors, Chemokine immunology
- Abstract
Myeloid derived suppressor cells (MDSCs) play a critical role in suppression of immune responses in cancer and inflammation. Here, we describe how regulation of Bcl2a1 by cytokines controls the suppressor function of CD11b(+) Gr-1(high) granulocytic MDSCs. Coculture of CD11b(+) Gr-1(high) granulocytic MDSCs with antigen-stimulated T cells and simultaneous blockade of IFN-γ by the use of anti-IFN-γ blocking antibody, IFN-γ(-/-) effector T cells, IFN-γR(-/-) MDSCs or STAT1(-/-) MDSCs led to upregulation of Bcl2a1 in CD11b(+) Gr-1(high) cells, improved survival, and enhanced their suppressor function. Molecular studies revealed that GM-CSF released by antigen-stimulated CD8(+) T cells induced Bcl2a1 upregulation, which was repressed in the presence of IFN-γ by a direct interaction of phosphorylated STAT-1 with the Bcl2a1 promotor. Bcl2a1 overexpressing granulocytic MDSCs demonstrated prolonged survival and enhanced suppressor function in vitro. Our data suggest that IFN-γ/ STAT1-dependent regulation of Bcl2a1 regulates survival and thereby suppressor function of granulocytic MDSCs., (© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2014
- Full Text
- View/download PDF
36. Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases.
- Author
-
Medina-Echeverz J, Fioravanti J, Díaz-Valdés N, Frank K, Aranda F, Gomar C, Ardaiz N, Dotor J, Umansky V, Prieto J, and Berraondo P
- Subjects
- Animals, CD3 Complex metabolism, Colorectal Neoplasms drug therapy, Colorectal Neoplasms metabolism, Female, Genetic Vectors, Granulocyte-Macrophage Colony-Stimulating Factor metabolism, Hepatocytes metabolism, Interferon-gamma metabolism, Liver metabolism, Liver Neoplasms drug therapy, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Neoplasm Metastasis prevention & control, Plasmids metabolism, Proto-Oncogene Proteins c-akt metabolism, Proto-Oncogene Proteins c-ret genetics, Transforming Growth Factor beta1 antagonists & inhibitors, Colorectal Neoplasms pathology, Lipoproteins, HDL pharmacology, Liver Neoplasms metabolism, Liver Neoplasms pathology, Molecular Targeted Therapy, Transforming Growth Factor beta1 metabolism
- Abstract
Transforming growth factor β (TGF-β) is a powerful promoter of cancer progression and a key target for antitumor therapy. As cancer cells exhibit active cholesterol metabolism, high density lipoproteins (HDLs) appear as an attractive delivery system for anticancer TGFβ-inhibitory molecules. We constructed a plasmid encoding a potent TGF-β-blocking peptide (P144) linked to apolipoprotein A-I (ApoA-I) through a flexible linker (pApoLinkerP144). The ApoLinkerP144 sequence was then incorporated into a hepatotropic adeno-associated vector (AAVApoLinkerP144). The aim was to induce hepatocytes to produce HDLs containing a modified ApoA-I capable of blocking TGF-β. We observed that transduction of the murine liver with pApoLinkerP144 led to the appearance of a fraction of circulating HDL containing the fusion protein. These HDLs were able to attenuate TGF-β signaling in the liver and to enhance IL-12 -mediated IFN-γ production. Treatment of liver metastasis of MC38 colorectal cancer with AAVApoLinkerP144 resulted in a significant reduction of tumor growth and enhanced expression of IFN-γ and GM-CSF in cancerous tissue. ApoLinkerP144 also delayed MC38 liver metastasis in Rag2-/-IL2rγ-/- immunodeficient mice. This effect was associated with downregulation of TGF-β target genes essential for metastatic niche conditioning. Finally, in a subset of ret transgenic mice, a model of aggressive spontaneous metastatic melanoma, AAVApoLinkerP144 delayed tumor growth in association with increased CD8+ T cell numbers in regional lymph nodes. In conclusion, modification of HDLs to transport TGF-β-blocking molecules is a novel and promising approach to inhibit the growth of liver metastases by immunological and non-immunological mechanisms.
- Published
- 2014
- Full Text
- View/download PDF
37. Myeloid-derived cells are key targets of tumor immunotherapy.
- Author
-
Medina-Echeverz J, Aranda F, and Berraondo P
- Abstract
Tumors are composed of heterogeneous cell populations recruited by cancer cells to promote growth and metastasis. Among cells comprising the tumor stroma, myeloid-derived cells play pleiotropic roles in supporting tumorigenesis at distinct stages of tumor development. The tumor-infiltrating myeloid cell contingent is composed of mast cells, neutrophils, dendritic cells, macrophages, and myeloid-derived suppressor cells. Such cells are capable of evading the hostile tumor environment typically prone to immune cell destruction and can even promote angiogenesis, chronic inflammation, and invasion. This paper briefly summarizes the different myeloid-derived subsets that promote tumor development and the strategies that have been used to counteract the protumorigenic activity of these cells. These strategies include myeloid cell depletion, reduction of recruitment, and inactivation or remodeling of cell phenotype. Combining drugs designed to target tumor myeloid cells with immunotherapies that effectively trigger antitumor adaptive immune responses holds great promise in the development of novel cancer treatments.
- Published
- 2014
- Full Text
- View/download PDF
38. Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses.
- Author
-
Quetglas JI, Rodriguez-Madoz JR, Bezunartea J, Ruiz-Guillen M, Casales E, Medina-Echeverz J, Prieto J, Berraondo P, Hervas-Stubbs S, and Smerdou C
- Subjects
- Adenocarcinoma immunology, Adenocarcinoma prevention & control, Adenocarcinoma virology, Alphavirus Infections immunology, Alphavirus Infections prevention & control, Alphavirus Infections virology, Animals, CD8-Positive T-Lymphocytes immunology, Cell Line, Cells, Cultured, Colorectal Neoplasms immunology, Colorectal Neoplasms prevention & control, Colorectal Neoplasms virology, Cricetinae, Female, Genetic Vectors administration & dosage, Genetic Vectors immunology, Genetic Vectors metabolism, Interleukin-12 genetics, Liver Neoplasms, Experimental virology, Mice, Mice, Inbred C57BL, Interleukin-12 biosynthesis, Liver Neoplasms, Experimental immunology, Liver Neoplasms, Experimental prevention & control, Semliki forest virus immunology, Semliki forest virus metabolism
- Abstract
Semliki Forest virus vectors expressing IL-12 (SFV-IL-12) were shown to induce potent antitumor responses against s.c. MC38 colon adenocarcinomas in immunocompetent mice. However, when MC38 tumors were implanted in liver, where colon tumors usually metastasize, SFV-IL-12 efficacy was significantly reduced. We reasoned that characterization of immune responses against intrahepatic tumors in responder and nonresponder animals could provide useful information for designing more potent antitumor strategies. Remarkably, SFV-IL-12 induced a high percentage of circulating tumor-specific CD8 T cells in all treated animals. Depletion studies showed that these cells were essential for SFV-IL-12 antitumor activity. However, in comparison with nonresponders, tumor-specific cells from responder mice acquired an effector-like phenotype significantly earlier, were recruited more efficiently to the liver, and, importantly, persisted for a longer period of time. All treated mice had high levels of functional specific CD8 T cells at 8 d posttreatment reflected by both in vivo killing and IFN-γ-production assays, but responder animals showed a more avid and persistent IFN-γ response. Interestingly, differences in immune responses between responders and nonresponders seemed to correlate with the immune status of the animals before treatment and were not due to the treatment itself. Mice that rejected tumors were protected against tumor rechallenge, indicating that sustained memory responses are required for an efficacious therapy. Interestingly, tumor-specific CD8 T cells of responder animals showed upregulation of IL-15Rα expression compared with nonresponders. These results suggest that SFV-IL-12 therapy could benefit from the use of strategies that could either upregulate IL-15Rα expression or activate this receptor.
- Published
- 2013
- Full Text
- View/download PDF
39. How can chemoimmunotherapy best be used for the treatment of colon cancer?
- Author
-
Medina-Echeverz J and Berraondo P
- Subjects
- Combined Modality Therapy, Humans, Adjuvants, Immunologic therapeutic use, Colonic Neoplasms therapy, Drug Therapy methods, Immunotherapy methods
- Published
- 2012
- Full Text
- View/download PDF
40. The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism.
- Author
-
Fioravanti J, Medina-Echeverz J, Ardaiz N, Gomar C, Parra-Guillén ZP, Prieto J, and Berraondo P
- Subjects
- Animals, Apolipoprotein A-I genetics, Depression drug therapy, Depression etiology, Female, Half-Life, Hindlimb Suspension, Humans, Injections, Intravenous, Interferon-alpha genetics, Lipoproteins, HDL metabolism, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Protein Transport, Recombinant Fusion Proteins genetics, Apolipoprotein A-I metabolism, Blood-Brain Barrier metabolism, Interferon-alpha metabolism, Recombinant Fusion Proteins pharmacokinetics
- Abstract
IFN-α is widely used for the treatment of chronic viral hepatitis and malignancies. However, systemic IFN-α treatment causes severe neuropsychiatric complications in humans, including depression, anxiety, and cognitive impairments. We have previously reported that the fusion protein formed by IFN-α and apolipoprotein A-I (IA) circulates bound to high-density lipoproteins (HDLs) and exhibits liver targeting, increased half-life, enhanced immunostimulatory activity, and reduced cytotoxicity. As the transport of HDLs across the blood-brain barrier is a highly complex and regulated process, in this study, we examine the effects of IA on the brain. Determination of IFN-α in brain and serum after hydrodynamic administration of different doses of a plasmid encoding IFN-α or IA showed that IA penetrated into the brain by a saturable transport mechanism. Thus, at high serum levels of the transgenes, the induction of IFN-sensitive genes and the number of phospho-STAT1(+) cell nuclei in the brain were substantially higher with IFN-α than with IA. This was associated with attenuation of neurodepression in mice given IA, as manifested by shorter immobility time in the tail suspension test. However, when given low doses of rIFN-α or the same antiviral units of HDLs containing IA, the induction of IFN-stimulated genes in the brain was significantly greater with the latter. In conclusion, IA crosses the blood-brain barrier not by diffusion, as is the case of IFN-α, but by a facilitated saturable transport mechanism. Thus, linkage to apolipoprotein A-I may serve to modulate the effects of IFN-α on the CNS.
- Published
- 2012
- Full Text
- View/download PDF
41. Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I.
- Author
-
Parra-Guillen ZP, Fioravanti J, Medina-Echeverz J, Gomar C, Ardaiz N, Troconiz IF, and Berraondo P
- Subjects
- Animals, Brain metabolism, Female, HEK293 Cells, Humans, Kinetics, Mice, Mice, Inbred BALB C, Models, Biological, Apolipoprotein A-I metabolism, Computer Simulation, Interferon-alpha metabolism, Recombinant Fusion Proteins metabolism
- Abstract
Interferon alpha linked to apolipoprotein A-I has been recently proposed as an improved interferon-based therapy. In the present study, we aimed to develop a computational model to gain further insight into the in vivo behaviour of this new fusion protein. In order to facilitate in vivo evaluation of interferon and the fusion protein without altering their biological properties, green fluorescent protein was incorporated into their structures. Kinetic and dynamic behaviour of both compounds was successfully described after plasmid hydrodynamic administration and in situ synthesis of the studied proteins. Results from the modelling exercise showed that apolipoprotein A-I conferred a modified kinetic behaviour, varying molecule distribution and prolonging half-life without altering liver dynamic performance. However, differences in the gene expression activity were observed at brain level between both compounds. Those differences could be explained by modifications in the dynamic, but also in the biodistribution properties, which would be worth evaluating in future experiments. Therefore, the modelling approach provided a global comprehension of a complex system and allowed us to compare the in vivo behaviour of both compounds and to identify critical aspects that might be important to understand the system better and suggests a need for new model-based experiments.
- Published
- 2012
- Full Text
- View/download PDF
42. Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.
- Author
-
Ochoa MC, Fioravanti J, Duitman EH, Medina-Echeverz J, Palazon A, Arina A, Dubrot J, Alfaro C, Morales-Kastresana A, Murillo O, Hervas-Stubbs S, Prieto J, Berraondo P, and Melero I
- Subjects
- Animals, Apolipoprotein A-I blood, Blotting, Western, CD8-Positive T-Lymphocytes immunology, Cell Count, Cell Line, Tumor, Cell Proliferation, Humans, Immunologic Memory, Injections, Subcutaneous, Interleukin-15 blood, Interleukin-15 Receptor alpha Subunit chemistry, Interleukin-15 Receptor alpha Subunit metabolism, Killer Cells, Natural immunology, Mice, Mice, Inbred C57BL, Neoplasm Metastasis, Phenotype, Protein Structure, Tertiary, Recombinant Proteins genetics, Recombinant Proteins therapeutic use, Spleen metabolism, Gene Transfer Techniques, Genetic Therapy, Immunotherapy, Interleukin-15 genetics, Interleukin-15 therapeutic use, Lipoproteins, HDL blood, Liver metabolism
- Abstract
Apolipoprotein A-I (Apo A-I) is a major component of high density lipoproteins (HDL) that transport cholesterol in circulation. We have constructed an expression plasmid encoding a chimeric molecule encompassing interleukin-15 (IL-15) and Apo A-I (pApo-hIL15) that was tested by hydrodynamic injections into mice and was co-administered with a plasmid encoding the sushi domain of IL-15Rα (pSushi) in order to enhance IL-15 trans-presentation and thereby bioactivity. The pharmacokinetics of the Apo A-I chimeric protein were much longer than non-stabilized IL-15 and its bioactivity was enhanced in combination with IL-15Rα Sushi. Importantly, the APO-IL-15 fusion protein was incorporated in part into circulating HDL. Liver gene transfer of these constructs increased NK and memory-phenotype CD8 lymphocyte numbers in peripheral blood, spleen and liver as a result of proliferation documented by CFSE dilution and BrdU incorporation. Moreover, the gene transfer procedure partly rescued the NK and memory T-cell deficiency observed in IL-15Rα(-/-) mice. pApo-hIL15+ pSushi gene transfer to the liver showed a modest therapeutic activity against subcutaneously transplanted MC38 colon carcinoma tumors, that was more evident when tumors were set up as liver metastases. The improved pharmacokinetic profile and the strong biological activity of APO-IL-15 fusion protein holds promise for further development in combination with other immunotherapies.
- Published
- 2012
- Full Text
- View/download PDF
43. Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells.
- Author
-
Medina-Echeverz J and Berraondo P
- Abstract
Interleukin-12 immune stimulation lacks efficacy in established solid tumor models. Disruption of tumor microenvironment homeostasis by low-dose cyclophosphamide prior to interleukin-12 gene therapy led to CD8+ T cell-driven established tumor rejection. This only takes place when inflammatory myeloid cells infiltrate the tumor bed, and is crucial for the latter antitumor response.
- Published
- 2012
- Full Text
- View/download PDF
44. Characterization of woodchuck apolipoprotein A-I: a new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model.
- Author
-
Fioravanti J, Gomar C, Medina-Echeverz J, Otano I, Benito A, Prieto J, González-Aseguinolaza G, and Berraondo P
- Subjects
- Animals, Base Sequence, Carbocyanines analysis, Cell Line, Tumor, Cloning, Molecular, Disease Models, Animal, Drug Delivery Systems methods, Flow Cytometry, Hepatitis B Virus, Woodchuck growth & development, Hepatitis B, Chronic metabolism, Hepatitis B, Chronic pathology, Humans, Liver pathology, Liver virology, Liver Neoplasms metabolism, Liver Neoplasms pathology, Marmota genetics, Marmota metabolism, Mice, Molecular Sequence Data, Molecular Targeted Therapy methods, Transfection, Virus Replication, Apolipoprotein A-I genetics, Apolipoprotein A-I isolation & purification, Apolipoprotein A-I metabolism, Carcinoma, Hepatocellular, Hepatitis B, Chronic genetics, Hepatitis B, Chronic virology, Liver Neoplasms genetics, Liver Neoplasms virology, Marmota virology, Protein Isoforms genetics, Protein Isoforms isolation & purification, Protein Isoforms metabolism
- Abstract
Apolipoprotein A-I (ApoA-I) is the major protein component of high density lipoprotein (HDL) particles in serum, and participates in the reverse transport of cholesterol from tissues to the liver for excretion. The natural HDL tropism to the liver and cancer cells has been used extensively to target encapsulated drugs. The alteration of the plasmatic isoforms of ApoA-I is a hallmark of chronic hepatitis and hepatocarcinoma in mice and humans. Woodchucks infected with the woodchuck hepatitis virus (WHV) represent the best animal model for the study of chronic viral hepatitis B and viral induced hepatocarcinoma (HCC). WHV-infected woodchuck represents a clinically relevant animal model under which new treatment strategies can be evaluated and optimized. Therapeutic efficacy in this model is likely to be translated into a successful therapy for patients infected with HBV. The present study describes, for the first time, the cloning and characterization of woodchuck ApoA-I. The open reading frame (ORF) of the woodchuck ApoA-I is 795 bp long, coding for 264 amino acids. Unexpectedly, phylogenetic analysis revealed that the closest sequences are those of human and macaque. Woodchuck HDLs were isolated successfully from sera by density gradient ultracentrifugation. A commercial antibody that recognized the woodchuck ApoA-I was also identified. Finally, taking advantage of the techniques and tools developed in this study, two potential applications of woodchuck HDLs are illustrated: drug delivery to a woodchuck hepatocarcinoma cell line and the use of isoelectrofocusing to identify ApoA-I isoforms., (Copyright © 2011 Wiley-Liss, Inc.)
- Published
- 2011
- Full Text
- View/download PDF
45. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties.
- Author
-
Fioravanti J, González I, Medina-Echeverz J, Larrea E, Ardaiz N, González-Aseguinolaza G, Prieto J, and Berraondo P
- Subjects
- Animals, Antiviral Agents pharmacokinetics, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Apolipoprotein A-I pharmacology, Apolipoprotein A-I therapeutic use, Apoptosis drug effects, CD36 Antigens genetics, CD36 Antigens physiology, Cell Line, Cell Line, Tumor, Disease Models, Animal, Female, Half-Life, Hepacivirus drug effects, Hepacivirus isolation & purification, Hepatitis C drug therapy, Hepatitis C physiopathology, Interferon-alpha pharmacology, Interferon-alpha therapeutic use, Lymphocytes drug effects, Lymphocytes pathology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Receptor Cross-Talk physiology, Receptor, Interferon alpha-beta physiology, Recombinant Fusion Proteins pharmacology, Recombinant Fusion Proteins therapeutic use, Apolipoprotein A-I pharmacokinetics, Hepatitis C immunology, Immunization, Interferon-alpha pharmacokinetics, Liver metabolism, Liver virology, Recombinant Fusion Proteins pharmacokinetics
- Abstract
Unlabelled: Interferon alpha (IFNα) is widely used for the treatment of viral hepatitis but substantial toxicity hampers its clinical use. In this work, we aimed at improving the efficacy of IFNα therapy by increasing the IFNα half-life and providing liver tropism. We selected apolipoprotein A-I (ApoA-I) as the stabilizing and targeting moiety. We generated plasmids encoding IFNα, albumin bound to IFNα (ALF), or IFNα linked to ApoA-I (IA) and mice were treated either by hydrodynamic administration of the plasmids or by injection of the corresponding recombinant proteins or high-density lipoproteins containing IA. The plasma half-life of IA was intermediate between IFNα and ALF. IA was targeted to the liver and induced higher hepatic expression of interferon-stimulated genes than IFNα or even ALF. IA exhibits stronger in vivo antiviral activity than IFNα and the hematologic cytopenic effects of IA are milder than those observed when using IFNα or ALF. In contrast to IFNα, IA does not cause activation-dependent cell death of lymphocytes in vitro. Accordingly, in vivo studies showed that IA boosts T-cell immune responses more efficiently than IFNα or ALF. The difference in immunostimulatory activity between IFNα and IA disappears in scavenger receptor class B type I (SR-BI) knockout mice, suggesting that crosstalk between SR-BI and IFNα receptor is essential for enhanced induction of cytotoxic T cells by IA., Conclusion: Anchoring IFNα to ApoA-I prolongs the half-life of IFNα and promotes targeting to the liver. Importantly, the fusion protein shows increased immunostimulatory properties and lower hematological toxicity., (Copyright © 2011 American Association for the Study of Liver Diseases.)
- Published
- 2011
- Full Text
- View/download PDF
46. Scavenger receptor class B, type I: a promising immunotherapy target.
- Author
-
Fioravanti J, Medina-Echeverz J, and Berraondo P
- Subjects
- Animals, Antigen Presentation immunology, Biological Transport, Cholesterol metabolism, Cross-Priming immunology, Humans, Immunotherapy, Lipoproteins, HDL metabolism, Mice, Signal Transduction, Toll-Like Receptors metabolism, CD36 Antigens chemistry, CD36 Antigens immunology, CD36 Antigens metabolism, Immunity physiology, Inflammation immunology
- Abstract
Scavenger receptor class B, type I (SR-BI) is a crucial molecule in lipid metabolism, since the interaction of high-density lipoproteins (HDLs) with SR-BI is involved in reverse cholesterol transport and cholesterol efflux. Recent findings also underscore a critical role of SR-BI in antimicrobial and immune responses. SR-BI is not only highly expressed in liver and steroidogenic glands, but also in endothelial cells, macrophages and dendritic cells. SR-BI mainly mediates anti-inflammatory responses, which may be altered by dysfunctional HDLs produced in several diseases. Moreover, SR-BI has been involved in the capture and cross-presentation of antigens from viruses, bacteria and parasites. It thus works as a pattern-recognition receptor that interacts with both damage-associated molecular patterns and pathogen-associated molecular patterns. These new findings in the microbiology and immunology fields present SR-BI as an unexplored therapeutic target that warrants further basic and applied research.
- Published
- 2011
- Full Text
- View/download PDF
47. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice.
- Author
-
Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, Berraondo P, Crettaz J, Gonzalez-Aseguinolaza G, Prieto J, and Hernandez-Alcoceba R
- Subjects
- Animals, Colorectal Neoplasms immunology, Combined Modality Therapy, Down-Regulation drug effects, Female, Genetic Vectors, Immune Tolerance drug effects, Interleukin-12 genetics, Liver metabolism, Liver Neoplasms immunology, Liver Neoplasms therapy, Mice, Mice, Inbred C57BL, Mice, Nude, Mifepristone pharmacology, Oxaliplatin, Transduction, Genetic, Tumor Microenvironment immunology, Xenograft Model Antitumor Assays, Antineoplastic Agents therapeutic use, Genetic Therapy methods, Interleukin-12 biosynthesis, Liver Neoplasms secondary, Organoplatinum Compounds therapeutic use
- Abstract
Background and Aims: New options are needed for the management and prevention of colorectal cancer liver metastases. Interleukin 12 (IL-12) is an immunostimulatory cytokine with proven antitumour effect in animal models. Despite evidence indicating its biological effect in humans, neither the recombinant protein nor gene therapy vectors expressing IL-12 have shown a relevant benefit in patients with cancer., Objective: To develop a new approach to overcome the difficulties in obtaining a suitable expression pattern and the immunosuppressive milieu in the tumours which contribute to this poor performance., Methods: A high-capacity ('gutless') adenoviral vector carrying a liver-specific, mifepristone (Mif)-inducible system for the expression of IL-12 (HC-Ad/RUmIL-12) was used in combination with chemotherapy. Tumours were established in the liver of C57BL/6 mice by inoculation of MC38 colon cancer cells., Results: Intrahepatic injection of HC-Ad/RUmIL-12 and tailored induction regimens allowed the maintenance of safe and efficient levels of IL-12 in vivo. An individualised, stepwise increase in the dose of Mif (125-4000 μg/kg) was needed to compensate for the progressive but transient downregulation of the inducible system. Repeated cycles of Mif induction (every 24 h for 10 days) were needed for optimal tumour eradication. However, complete protection against tumour rechallenge was seen in < 25% of the animals. The administration of oxaliplatin (5 mg/kg intraperitoneally) 3 days before starting the induction regimen achieved efficient elimination of liver metastases with a single cycle of IL-12 induction, and improved protection against tumour rechallenge. This was associated with a shift in the tumour microenvironment towards a more pro-immunogenic phenotype, with an increase in the CD8+/T regulatory cell ratio and a reduction in myeloid-derived suppressor cells. These effects were not seen with 5-fluorouracil, irinotecan or gemcitabine., Conclusions: Long-term controlled expression of IL-12 using an HC-Ad vector in combination with oxaliplatin is effective and clinically applicable against hepatic colon cancer metastases.
- Published
- 2011
- Full Text
- View/download PDF
48. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells.
- Author
-
Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, and Berraondo P
- Subjects
- Animals, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Cell Line, Tumor, Colonic Neoplasms pathology, Combined Modality Therapy, Cyclophosphamide administration & dosage, Female, Genetic Therapy methods, Inflammation drug therapy, Inflammation immunology, Inflammation pathology, Interleukin-12 administration & dosage, Interleukin-12 genetics, Interleukin-12 therapeutic use, Interleukin-2 Receptor alpha Subunit antagonists & inhibitors, Interleukin-2 Receptor alpha Subunit immunology, Lymph Nodes immunology, Lymph Nodes pathology, Macrophages immunology, Macrophages pathology, Mice, Mice, Inbred C57BL, Monocytes immunology, Monocytes pathology, Myeloid Cells drug effects, Neoplasms, Experimental pathology, Neutrophils immunology, Neutrophils pathology, Spleen immunology, Spleen pathology, Colonic Neoplasms drug therapy, Colonic Neoplasms immunology, Immunophenotyping, Myeloid Cells immunology, Myeloid Cells pathology, Neoplasms, Experimental drug therapy, Neoplasms, Experimental immunology
- Abstract
IL-12 is a potent immunostimulatory cytokine, but its impact as an antitumor drug in clinical practice is limited. Upsurge of regulatory T cells (Treg) in the tumor milieu has been proposed to limit the efficacy of the treatment. In this paper, two drugs (cyclophosphamide [CPA] and anti-CD25 mAb) widely used to eliminate Treg were used in an attempt to enhance the antitumor effect of IL-12 gene therapy. Both anti-CD25 and CPA combined with IL-12 were able to deplete intratumoral Treg and myeloid-derived suppressor cells (MDSC), but only IL-12 plus CPA achieved significant antitumor activity in mice with large established s.c. colon carcinoma. This therapeutic effect was associated with the emergence of a heterogeneous population of myeloid cells within the tumor, termed inflammatory myeloid cells (IMC), composed of Ly6C(high)Ly6G(low) inflammatory monocytes and Ly6G(high)Ly6C(+) neutrophils. IMC showed a distinctive pattern of cytokine/chemokine production, and in contrast to MDSC, they did not induce conversion of naive CD4(+) T cells into Treg. The appearance of IMC coincided with intense tumor infiltration by effector T cells, which was abrogated by elimination of IMC by anti-Gr1 mAb, a maneuver that abolished the antitumor effect of the therapy. Therefore, the combination of IL-12 and CPA eliminates intratumoral Treg and MDSC, while it induces the appearance of IMC within the tumor microenvironment. The latter effect is essential to facilitate effector T cell infiltration and subsequent tumor elimination.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.